Myriad Genetic (MYGN) shares jumped 8% to $87.91 on Wednesday, following news that the American College of Obstetricians and Gynecologists is recommending doctors routinely evaluate whether a patient is at risk of carrying a genetic mutation of the BRCA1 or BRCA2 gene.

As carriers of the mutation generally have a markedly higher risk of developing breast or ovarian cancer, doctors may choose to take preventative measures, such as removal of the ovaries and fallopian tubes.

Myriad markets a genetic screening test for the BRCA1 and BRCA2 mutations called BRACAnalysis.